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blocked cell death pathways,
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Piet Borst
Molecular Oncology, NKI-AVL, Plesmanlaan 121, Amsterdam, The Netherlands
1. Summary
Although chemotherapy of tumours has scored successes, drug resistance
remains the major cause of death of cancer patients. Initial treatment often
leaves residual disease, from which the tumour regrows. Eventually, most
tumours become resistant to all available chemotherapy. I call this pan-resistance
to distinguish it from multi-drug resistance, usually describing resistance caused
by upregulation of drug transporters, such as P-glycoprotein. In this review, I
discuss mechanisms proposed to explain both residual disease and pan-
resistance. Although plausible explanations are at hand for residual disease,
pan-resistance is still a mystery. My conclusion is that it is time for a major
effort to solve this mystery using the new genetically modified mouse tumour
models that produce real tumours resembling cancer in human patients.
2. Introduction
Most patients with disseminated cancer die because their metastases become
resistant to all available drugs. Often resistance arises in two steps. Initially,
the tumour responds to the drug, but not all tumour cells are killed. This
residual disease eventually gives rise to tumours that do not respond to any
drug anymore [1]. I call this pan-resistance, a term borrowed from bacteriology
[2], to distinguish it from multi-drug resistance (MDR), classically used to
describe resistance caused by promiscuous drug transporters. These can
extrude many drugs from cancer cells, but not all, and they can therefore not
cause pan-resistance. As we learn more about cancer and about mechanisms
of resistance, explanations for residual disease and for pan-resistance of
tumours in the terminally ill have proliferated. Here I discuss the evidence
for these explanations. Although residual disease and pan-resistance are funda-
mentally different, the mechanisms causing resistance overlap. I therefore use
residual disease as the overture to the main topic, pan-resistance.
Drug resistance is a vast research field. To stay within the word count
allotted, my treatment of the subject is therefore selective, if not idiosyncratic.
To economize on references, I liberally quote reviews that I consider sound.
& 2012 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/3.0/, which permits unrestricted use, provided the original
author and source are credited.3. Some introductory comments on
drug resistance
Often investigators think about drug resistance of cancer
cells in the same terms as drug resistance of bacteria. Well-
behaving bacteria should be sensitive to the antibiotics that
we aim at them. They may become resistant by mutation or
adaptation; they may hide in body sanctuaries, where the
drugs do not reach them; but basically, if we use the right
drug, the bacterium should respond and die. To transpose
this expectation to cancer cells without modification is unrea-
listic. Cancer cells are body cells that misbehave; basically,
their proteins and metabolic pathways are the same as in
normal host cells. With few exceptions, cancer cells do not
have enzymic reactions that are completely absent in
normal cells, like cell wall synthesis, which can be targeted
in bacteria without hitting mammalian cells. The ground
state of cancer cells is resistance, not sensitivity. If drugs hit
cancer cells more than do normal cells, it is only because
the cancerous state has entailed cellular changes that make
the cell more vulnerable. The term ‘primary drug resistance’
for tumours that do not respond at all is therefore misleading.
The cells are not resistant, they are just not more sensitive to
the drug than normal cells. Tumour cells that do respond are
more vulnerable than normal cells and are really hypersensi-
tive to the drug, as first pointed out by the British medical
oncologist Adrian Harris [3]. If hit by a drug in that Achilles
heel [4,5], the tumour cell may develop secondary resistance,
levelling the playing field and reducing its drug sensitivity
to that of normal cells. The general belief in the cancer
field is that tumours have a sufficient number of Achilles
heels that we shall eventually be able to destroy any
tumour anywhere in the body. Maybe; let us hope so.
Obviously, drugs can work only when they reach the
tumourcells.That does notalwaysoccur.Therearesanctuaries
in the body, where tumour cells are hard to reach. An interest-
ing recent example is provided by the results of neo-adjuvant
therapy of breast cancer, used to shrink the tumour before
operation. The tumour may have disappeared from the
breast by this treatment, but in some cases, metastases
appear later in the brain [6] (S. Rodenhuis 2012, personal com-
munication), where tumour cells have escaped from the drugs
given to the patient by hiding behind the blood–brain barrier
[7]. There are also well-documented cases of tumours that are
poorly penetrable by drugs, because of a massive stromal
component (e.g. pancreatic cancer [8,9]) or elevated intratu-
moral pressure. These ‘mechanical forms’ of resistance will be
disregarded here. This review deals with biochemical mechan-
isms of resistance. This does not imply that tumour cells are
impervious to their surroundings. However, the evidence
that the interaction with stromal cells affects the resistance of
tumour cells is not compelling, in my opinion. Notably, the
notion that chemotherapeutic agents may act by inducing an
immune response against the tumour [10] is not supported
by evidence from realistic non-immunogenic mouse tumour
models [11], nor from human cancer patients.
4. Pumps
Historically, the drug export transporter P-glycoprotein
(P-gp) [12], encoded by the ABCB1 (MDR1) gene in
humans, has shaped ideas about MDR. This pump can
remove a large range of drugs from the cell, and upregulation
of P-gp makes it possible for cancer cells to become comple-
tely resistant to some of the drugs intensively used in the
clinic, notably taxanes, anthracyclines, epipodophylotoxins
and Vinca alkaloids [13]. Understandably, the discovery of
a major form of MDR led to an optimistic sentiment in the
field that all forms of drug resistance would soon be under-
stood and, hence, overcome. From the start, it was clear,
however, that even the versatile P-gp could only handle a
limited number of amphipathic compounds that penetrate
the membrane slow enough to be intercepted by an export
pump. A host of other drugs—hydrophilic large drugs
(methotrexate), nucleoside analogues (F-uracil) and nearly
all alkylating agents—are poor P-gp substrates. The expec-
tation that other pumps would turn up that would handle
the drugs not transported by P-gp has also not materialized
[14,15]. Some amphipathic drugs with low affinity for P-gp,
such as the camptothecins/topotecan, are transported by
BCRP (ABCG2) [16] and MDR Protein 4 (MRP4; ABCC4),
but no general pumps have been found for alkylating
agents [17]. Most of the transporters in the large ABCC
(MRP) family have not been linked to resistance against
anti-cancer drugs [18]. Where this is the case, the substrate
specificity of these pumps overlaps with that of P-gp
or BCRP.
Some 35 years after the first drug transporter associated
with MDR was discovered, the sobering conclusion is that
the evidence for a substantial role of these transporters in
drug resistance in real tumours is limited. On the positive
side, there is no doubt that modest upregulation of P-gp
[19] or BCRP [20] can cause complete resistance to substrate
drugs in a mouse model of human BRCA1-mutated breast
cancer. Other transporters have not been found, however,
as mediators of drug resistance in this model. The evidence
for a role of any of these transporters in resistance of
human cancers is largely negative as well. Effective inhibitors
of P-gp have shown only limited effects in clinical trials
[21,22]. There is no evidence that upregulation of other
ABC transporters is consistently associated with drug resist-
ance in human cancer patients. The lack of clinically
useful inhibitors for BCRP or MRPs has precluded a more
direct test of the possible contribution of those transporters
to resistance.
Why these effective drug transporters are not more pro-
minently used by human cancer cells in the defence against
drugs can only be guessed. One reason could be that
cancer patients are nearly always treated with drug cocktails
that contain drugs not transported by ABC-transporters.
Such tumours are primarily selected for resistance mechan-
isms that deal with all drugs simultaneously, rather than
one of these drugs, and pumps will then not do. Another
reason could be that the level of some of the most effective
transporters is very low in many human tissues/tumours,
lower than in mouse tissues/tumours. Hence, modest tran-
scriptional upregulation of P-gp in human tissues does not
result in transporter levels sufficient for resistance. Only dras-
tic upregulation will help. Indeed, in the unusual cases where
P-gp has been proved to contribute to resistance, the ABCB1
(P-gp) gene in the tumour is hooked up to a strong promoter
by a DNA rearrangement [23]. This is apparently a rare event.
The ABCB1 gene has not turned up as a gene predicting poor
response to neoadjuvant chemotherapy of breast cancer
r
s
o
b
.
r
o
y
a
l
s
o
c
i
e
t
y
p
u
b
l
i
s
h
i
n
g
.
o
r
g
O
p
e
n
B
i
o
l
2
:
1
2
0
0
6
6
2[24,25]. Even the neo-adjuvant therapy, in which breast
cancer patients are treated with anthracyclins or taxanes,
has not resulted in substantial upregulation of P-gp [26]
(J. de Ronde & L. Wessels 2012, personal communication),
although this is the predominant mechanism of resistance
against these drugs in a mouse model that closely resembles
human breast cancer [27]. I think that these results show that
not all drug resistance mechanisms are readily available in all
tumours, not even powerful ones such as export pumps.
5. Residual disease: cell cycle effects
It has been known from the early days of experimental drug
studies that cell cycle matters. This is hardly surprising. Most
enzymes making DNA and RNA will stall at DNA damage.
Non-cycling cells can take the time to repair the damage.
DNA-damaging agents will primarily hit cells in the
S-phase of the cell cycle and spindle poisons cells in mitosis.
Hence, cells in the G0/G1 phase of the cell cycle have long
been known to be relatively resistant to classical cytotoxic
therapy [28]. Indeed, even cells sensitized to DNA damage
by DNA repair defects are not uniformly killed by ionizing
irradiation or alkylating agents: there is always a long tail
in the dose–response curve [29]. Recent papers have explored
the possibility that tumours may contain a fraction of quies-
cent cells that is actively kept in a (reversible) drug-tolerant
state. I shall return to this a little later.
6. Residual disease: how do some
leukaemia cells escape
effective therapy?
Curative chemotherapy is seen only with some tumours with
a high proliferative index—leukaemias, lymphomas, testicu-
lar cancer—and these are the exceptions to the rule that
patients relapse, even if their tumours initially responded
to chemotherapy. The most informative studies on the
nature of the residual disease from which the relapse springs
have been done with the inhibitors of signal transduction
pathways, often called ‘targeted therapeutics’, a misnomer
disregarding the exquisite targeting of some of the classical
cytotoxic drugs, such as the topoisomerase poisons. In
the case of kinase inhibitors, such as imatinib (Gleevec), a
major mechanism of resistance is the presence of a small
sub-population of leukaemic cells in which the ABL kinase,
the target of imatinib, contains an amino acid substitution
that prevents inhibition by imatinib [30]. Such target-altering
mutations have also been observed with other kinase inhibi-
tors [31]. The tumour may also avoid the deleterious effect of
a road block in a signalling pathway to which it is addicted
by activating an alternative pathway that circumvents the
block. Such bypasses can explain resistance to HER2 or
B-RAF inhibition.
This is not the whole story. If the only reason that CML
caused by activation of ABL cannot be cured is the existence
of minor fractions of tumour cells with an ABL kinase
mutation, it should be possible to hit these sub-fractions
with second- and third-generation ABL kinases inhibitors
up front and to cure all CML [32]. If bypasses arise, around
the drug-induced signal transduction block, it should be
possible to inhibit these bypasses in turn with other drugs.
Although successes have been scored by this approach [33],
there are complications. One complication that seems to be
especially relevant to leukaemias/lymphomas is the gener-
ation of blocks in cell death [34]. In a recent paper, massive
upregulation of BCL6 was shown to protect an acute lympho-
blastic leukaemia against cell death resulting from a block in
ABL signalling. Inhibition of BCL6 sensitized the cells to ABL
inhibitors [35]. A more general complication is the presence of
a small fraction of cancer ‘stem’ cells, which is intrinsically
resistant, because of its quiescence (see later text). If these
cells are kicked into cycle by interferon-a, G-CSF or arsenic
trioxide, they become sensitive to cytotoxic drugs [36–38].
Although this approach is theoretically appealing, its trans-
lation to the clinic has thus far given equivocal results [39]
and factors other than quiescence may contribute to residual
disease in leukaemia [40]. A slowly multiplying fraction of
tumour cells was recently also identified in melanoma cells
[41]. Expression of the H3K4 demethylase JARID1B is essen-
tial for the maintenance of this fraction, which displays
tumour initiation ability. Although drug sensitivity of the
slow-cycling melanoma cells has not yet been tested, the
authors note that treatment with anti-cancer therapy in vitro
results in the enrichment of the JARID1B-positive cells.
The study of residual disease is difficult in animals
or humans. The cells are few, dispersed, and hard to isolate
and characterize. This is why investigators have attempted
to characterize a ‘residual disease’ fraction in cultured cells.
In §7, I discuss prominent examples of this type of study.
7. A chromatin-mediated reversible
drug-tolerant state in cancer cell
sub-populations
Sharma et al. [42] treated a non-small-cell lung cancer (NSCLC)
cell line with tyrosine kinase inhibitors (TKIs) targeting a
mutant version of the epidermal growth factor receptor.
Although the vast majority of the cells were killed, they
obtained a small fraction of cells that survived drug con-
centrations 100-fold above the IC50. These ‘drug-tolerant
persisters’ (DTPs) represent 0.3 to 5 per cent of the cell popu-
lation and are not stably resistant. When grown in the
absence of a drug, the cells rapidly regain drug sensitivity.
AdetailedinvestigationoftheDTPsshowedwidespreadaltera-
tions in gene expression, including several genes involved in
chromatin modification, such as increased KDM5A/Jarid1A,
a histone H3K demethylase and increased histone deacetylases
(HDACs). Depletion of the KDM5A demethylase, or treatment
of the cells with HDAC inhibitors, reduced the number of
DTPs, indicating that the widespread chromatin modifications
in the DTPs were responsible for resistance. The emergence
of DTPs in these NSCLC cells required signalling via the
IGF-1 receptor, as it could be prevented by an inhibitor of
this receptor.
Sharma et al. [42] found DTPs in all tumour cell lines
studied, including tumours originating from several different
tissues. Although DTPs were initially isolated by their resist-
ance to TKIs, DTPs are cross-resistant to cisplatin, suggesting
generalized (pan-) resistance. Unfortunately, other drugs or
X-rays were not investigated. The authors have also not yet
determined how the DTPs arise or why these cells are resist-
ant to drugs. One mode of generating slowly replicating cells
r
s
o
b
.
r
o
y
a
l
s
o
c
i
e
t
y
p
u
b
l
i
s
h
i
n
g
.
o
r
g
O
p
e
n
B
i
o
l
2
:
1
2
0
0
6
6
3was uncovered by Dey-Guha et al. [43]. In MCF7 cells multi-
plying in vitro, they observed occasional asymmetric
divisions, in which AKT was downregulated in one of the
daughter cells. This G0-like daughter then continued to repli-
cate slowly. Inhibition of AKT led to increased formation of
G0-like cells, and these cells were enriched in tumours after
cytotoxic treatment of breast cancer patients, suggesting
that the G0-like AKT-low cells could play a role in residual
disease. Unfortunately, it is still unclear how (and why)
cells decide to turn off AKT and generate a G0-like daughter.
In another tumour cell line, upregulation of the ATF6a tran-
scription factor promoted survival of dormant tumour cells in
nude mice [44]. ATF6a is known to act as a survival factor
after endoplasmic reticulum stress, and in this system it
acts on mTOR via an AKT-independent pathway.
The notion that cancer can be associated with widespread
epigenetic alterations is, of course, not new. Tumour suppres-
sor genes can be turned off epigenetically [45], and attempts
have been made to reverse this turn-off by DNA demethylat-
ing agents, by HDAC inhibitors and by combinations of both
inhibitors, with modest clinical success [46]. There are also
reports of synergistic effects of cytotoxic chemotherapy and
HDAC inhibitors [47]. Hauswald et al. [47] have pointed
out, however, that activation of silenced genes is a two-
edged sword, as resistance genes may be activated as well.
In AML cell lines, they showed that HDAC inhibitors acti-
vated the expression of a series of drug transporter genes
resulting in a pleiotropic resistance phenotype extending far
beyond classical MDR and including nucleoside analogues.
‘Epigenetic therapy’ will not be plain sailing.
Sharma et al. [42] have emphasized the resemblance of
drug-tolerant cancer cells with ‘persisters’ in bacterial popu-
lations. I think that this resemblance is a spurious one, but
I do not have space here to discuss this complex issue. Inter-
ested readers can find a justification for my scepticism in the
electronic supplementary material, appendix SI.
When DTPs are kept under drug pressure, they eventually
turn into ‘drug-tolerant expanded persisters’ (DTEPs), which
can multiply in the presence of a drug. This is not residual dis-
ease but real resistance, and I shall return to the DTEPs below.
8. Are cancer stem cells the key to
residual disease?
The cancer stem cell (CSC) concept has been succinctly sum-
marized by Hans Clevers ([48], p. 313) in an elegant and
critical review:
Central to the stem cell (CSC) concept is the observation that
not all cells in tumours are equal. The CSC concept postulates
that, similar to the growth of normal proliferative tissues such
as bone marrow, skin or intestinal epithelium, the growth of
tumours is fuelled by limited numbers of dedicated stem
cells that are capable of self-renewal. The bulk of a tumour
consists of rapidly proliferating cells as well as postmitotic, dif-
ferentiated cells. As neither of these latter two classes of cells
has the capacity to self-renew, the contribution of these non-
CSC tumour cells to the long-term sustenance of the tumour
is negligible.
It is not surprising that this CSC concept has fired the imagin-
ation of investigators working on drug resistance [49–51].
If tumours are driven by CSCs, the stem cells are the cells
that need to be killed to eradicate the tumour. Incomplete era-
dication of cancer must leave some of the CSCs untouched
and these are responsible for tumour relapse. Residual dis-
ease may therefore consist of stem cells equipped with
specialized drug resistance mechanisms. It follows that che-
motherapy aiming at cure should therefore target the CSCs
rather than the bulk of the tumour cells [50,51]. To eliminate
the weeds, you have to tear out the roots. If there were drugs
that kill rare CSCs without touching the bulk of the tumour
cells, they might even have been missed in standard
chemotherapy trials.
Since the CSC concept was revived by Dick and col-
leagues for acute myeloid leukaemia in 1995 and extended
to solid tumours in 2003, the concept has become the centre
of heated controversies [52], as summarized by Clevers [48].
Some investigators think that the CSC concept should
guide the search for new cancer therapies. In contrast,
others believe that CSCs of solid human tumours are an arte-
fact of the methods used to detect tumour-initiating cells
(TICs). This requires dissociation of the tumour into single
cells, fluorescence-activated cell sorting (FACS) and seeding
in artificial niches in immunocompromised mice. This assay
may select more for the ability of cells to survive extreme
insults than for stemness. These sceptical investigators
stress the flexibility of the tumour cell population, which
allows more differentiated cells to dedifferentiate into CSCs.
Obviously, if the CSC phenotype is not a stable trait, the
development of drugs specifically targeting CSCs becomes
less attractive [48,53]. If the phenotypic heterogeneity in
tumours is reversible, as Morrison and co-workers have
shown for melanomas [54], it becomes irrelevant to dis-
tinguish CSCs from the bulk population of cancer cells
when considering targeted therapy [48].
Although the CSC concept has lost some of its lustre, it is
still often invoked to explain residual disease. I shall therefore
briefly summarize the evidence that CSCs have specialized
defences against chemotherapy that could explain drug-
resistant residual disease:
— Drug transporters [49]. It is often stated that stem cells,
including CSCs, are rich in transporters able to extrude
drugs from cells. This idea seems to have its origin in
the haematopoietic stem cells, which indeed contain
high concentrations of the two most versatile drug
pumps, P-gp (MDR1, ABCB1) and BCRP (ABCG2).
Initially, ABCG2 was even thought to be a general
marker of stem cells, but more recent evidence has
shown this to be incorrect. For instance, the normal mam-
mary gland stem cell lacks ABCG2 [55,56]. Likewise, gut
stem cells lack P-gp [57]. For other transporters present
in CSCs, such as the MRPs (ABCCs), a generalized role
in drug resistance is improbable. The MRP most generally
present in cells, MRP1 (ABCC1), has never been conclus-
ively linked to resistance in either mouse model tumours
or human clinical samples [49]. Even if high levels of a
MDR-type drug transporter are found in some CSCs,
these can only explain resistance to substrates of the trans-
porter, not to the many prominent drugs not touched by
MDR transporters, as also pointed out by Dean [49].
— Resistance to DNA damage. The most unambiguous results
have been obtained with ionizing radiation, which is not
complicated by target alterations (e.g. topoisomerase
down regulation) or drug uptake problems encountered
by DNA-interacting drugs. The CD133-expressing
glioma cells with CSC properties are more resistant to
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4ionizing radiation than the CD133-negative tumour cells
[58] and the same holds for the putative CSC fraction of
human breast cancer [59]. Why is not known. It could
be due to more efficient repair of DNA strand breaks, or
to more CSCs being quiescent-like, allowing more time
for DNA repair before cells enter S-phase and find their
DNA too damaged to survive DNA replication.
— Quiescence. A low rate of multiplication is a hallmark of
the somatic stem cells of normal tissues, the majority of
colon epithelial stem cells being the exception [48,60].
Whether this makes stem cells less vulnerable to che-
motherapy is not self-evident. Blanplain and co-workers
[61] have claimed that being in G0/G1 when your DNA
gets hit can actually be unhealthy for a stem cell, as
duplex breaks in DNA cannot be repaired by the error-
free homology-directed system only available during
and after DNA replication. Instead, the error-prone
system of non-homologous end joining has to be used
to fix duplex DNA breaks. Nevertheless, the generally
accepted hypothesis is that quiescence of stem cells pro-
tects against cytotoxic therapy [48,62–64]. The presence
of quiescent cells with CSC properties has been demon-
strated in several tumour systems, using retention of
DNA label or lipophilic dye. Whether these are the cells
in the tumour that result in residual disease and whether
their quiescence is responsible for their survival remains
to be seen. The most convincing experiments have been
published by Andreas Trumpp and co-workers [36,37],
who showed that leukaemia stem cells could be targeted
by breaking their dormancy.
— Epithelial to mesenchymal transition (EMT). There is no
doubt that EMT provides a formidable version of pan-
resistance [65] and I shall return to this below. The question
here is whether residual disease is due to EMT. This ques-
tion is not easily answered, as EMT can be a transient
state that could be easily missed. Moreover, residual dis-
ease is usually poorly accessible to detailed analysis, and
often the analysis does not include an evaluation of EMT.
In the few model systems in which this was verified, no
EMT was found [66] and EMT therefore does not appear
to provide a general explanation for residual disease.
Are CSCs responsible for the therapy-resistant fraction
resulting in residual disease? This is obviously the key
question. There are now several tumour systems in which
CSC-like cells are enriched in tumour remnants after therapy.
These include gliomas, breast cancer, colon cancer and a soph-
isticated CML mouse model [48]. In our laboratory, Pajic et al.
[66] have studied the issue in a conditional mouse model of
human triple-negative breast cancer. In the mouse, the somatic
stem cells are well defined in normal mammary glands. Cells
with the same surface markers proved to be highly enriched
in the tumour-initiating fraction isolated from the tumour.
However, the few cells in thistumour repeatedlysurviving cis-
platin therapy were not enriched in these TICs. This raises the
question whether residual disease in other tumour systems is
really due to putative CSCs or a consequence of other proper-
tiesofCSCs,suchasquiescence,allowingthemtosurvivedrug
treatment.
A major effort is under way to find drugs that preferen-
tially target stem cells [67]. As pointed out by Clevers [48],
the initial ideas driving this effort were too simple. Tumours
have no roots that one can specifically tear out, dooming the
plant. There is little doubt that some of the more differen-
tiated tumour cells can dedifferentiate to replace the killed
CSCs. If CSC-targeted therapy is going to make a contri-
bution, it is only in conjunction with therapy targeting the
bulk of the tumour.
Zhou et al. [51] and Frank et al. [68] have written detailed
and optimistic reviews of the new therapeutic opportunities
provided by the CSC hypothesis. The drugs under develop-
ment mainly attempt to target signalling pathways involved
in the regulation of self-renewal of normal somatic stem
cells, such as the Wnt, the Sonic Hedgehog and the Notch
pathways. The drugs should either preferentially block stem
cell (and CSC) renewal or drive the stem cells into dif-
ferentiation, closing down the tumour supply line. As the
authors point out, a major problem is specificity, as with all
tumour chemotherapy. Indeed, the only small molecule that
targets a pathway involving stem cell self-renewal and that
has managed to reach a phase II trial at the time the review
of Zhou et al. [51] was written is a SMO (Sonic Hedgehog)
antagonist. This was developed, however, for patients with
basal cell carcinoma, most of whom have mutations in
Hedgehog pathway components [69].
Other approaches attempt to target surface molecules pre-
ferentially present on CSCs [68]. Whether the (limited)
effectiveness of these antibodies against metastatic cancer is
due to their targeting of CSCs remains to be seen.
9. Residual disease: conclusions
In summary, of the many different explanations advanced for
residual disease: the old-fashioned one seems best supported
by experimental data: residual disease is due to quiescent
cells. These cells are not cells that just happen to be in G1,
but cells that have entered a specific quiescence programme.
This programme may involve widespread alterations in gene
expression that are reversible, allowing these cells to re-enter
the cell cycle when danger is gone. The analogy of these
quiescent cells with bacterial ‘persisters’ is misleading, in
my opinion, as explained in the electronic supplementary
material. Residual disease in cancer is not the expression of
a genetic programme that protects the population from total
destruction. It is a state of a small fraction of the tumour
cells that allow these cells to avoid being killed.
10. Pan-resistance: general considerations
The most frustrating and intractable form of resistance is pan-
resistance; resistance to any drug, and often also to ionizing
radiation. It is as if the cancer cell has lost all targetable
defects. Some targets can indeed be lost, as carcinogenesis
can be a hit-and-run process. For instance, DNA repair
defects are mutagenic and contribute to tumourigenesis,
but full-blown tumours do not need the defect to continue
growing. Hence, deficiencies in homology-dependent DNA
repair caused by downregulation or mutation of BRCA1/2
can be reversed in the mature tumour during drug treatment.
Methylation of the promoter may be reversed; chain-termi-
nating mutations can be mitigated by a second mutation
restoring the reading frame [70]. Although this removes an
obvious Achilles heel of the cancer cell that made it vulner-
able to drugs, the basic hallmarks of the cancer cell are not
altered and it continues to proliferate. Why are there no
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5obvious activated growth promoting pathways or failed cell
cycle checkpoints in pan-resistant cells that can be exploited
by available drugs? Quiescence is not an explanation: the
tumour continues to proliferate, whatever the medical
oncologist throws at it.
Basically, there are three types of explanations for pan-
resistance: mimicry, superior defence or compensation. Mimi-
cry of normal cells entails the adoption of proliferation
strategies of normal cells. Rather than relying on abnormal
activation of proliferation-promoting pathways, the cancer
cell blends in by imitating rapid growth of host tissues with
high turnover rates, making the tumour equally sensitive/
resistant to drugs as normal tissues. This is a theoretical
possibility that I find implausible. Normal cells are comple-
tely dependent on external signals for growth and it seems
unlikely that a tumour would be able to exploit normal
exogenous growth stimuli without the cost of any targetable
vulnerability. Nevertheless, I mention this possibility to re-
emphasize that tumour cells responding to drug are hyper-
sensitive to that drug relative to the normal cells in the
body. If they lose that hypersensitivity and become ‘resistant’
to all drugs, they have just levelled the playing field. And on
a level field, the cancer cell wins.
The two other explanations for pan-resistance—
superdefence and compensation—may seem two sides of
the same coin, but they are not. Superdefence is the ability
to keep all drugs away from their targets. P-gp upregulation
could be part of such a superdefence system. P-gp does not
affect drug targets in the cell or the vulnerability of the
tumour cell to drugs hitting those targets. P-gp only prevents
the drug from reaching its target. In contrast, compensation
represents adaptations that affect multiple targets in an indir-
ect way without influencing drug–target interaction (i.e.
increased DNA repair, or less dependence on a growth-
promoting activated signal-transduction pathway by
activation of a parallel pathway). The optimistic view is that
superdefence or compensatory adaptations both involve
alterations in gene expression that might be exploited by
drug treatment. Upregulated pumps can be targeted with
inhibitors; there are even attempts to develop drugs that
specifically hit cells with upregulated P-gp [71]. Activated par-
allelpathwaysmaybetargetedwithadditionaldrugs.Oncewe
know how the cancer cells avoid destruction by therapy, it is
hoped that we can adapt our therapeutic strategy.
Pan-resistance is tough to study. The most useful infor-
mation comes from model systems in which initial sensitivity
todrugsisreplacedduringtreatmentbypan-resistance.Unfor-
tunately, pan-resistance is usually accompanied by massive
alterations in gene expression, making it hard to pinpoint
which changes are actually responsible for the resistance.
I will discuss here the most informative systems studied.
11. Chromatin-mediated pan-resistance
Sharma et al. [42] have found a chromatin-mediated reversible
drug-tolerant state in cancer cell lines grown in vitro,a sd i s -
cussed earlier. Although these ‘DTPs’ are largely quiescent,
approximately 20 per cent of DTPs eventually resume
normal proliferation in the presence of a drug, yielding
‘DTEPs’, which can be propagated in drugs forever [42].
DTEPs, like DTPs, can be obtained from very different cell
lines and display widespread alterations in gene expression.
The drug-tolerant state of DTEPs is also unstable, but reversion
to drug sensitivity takes about 90 cell doublings, showing that
the drug-tolerant state has become stabilized to some extent in
the DTEPs. Like DTPs, formation of DTEPs can be inhibited by
downregulation of the histone H3K4 demethylase KDM5A
and by inhibition of HDAC activity. Cells originally selected
for resistance to TK inhibitors proved cross-resistant to cispla-
tin, indicating a broad mechanism of resistance, although no
other drugs were apparently tested. Why DTEPs are resistant
is not known. They are not really pan-resistant, as treatment
with HDAC inhibitors induces a DNA-damage response that
kills the cells. It should also be noted that resistance in this
system has only been studied in vitro. Whether the resistance
observed in test tubes is sufficient to make the tumour resistant
in animals remains to be seen. Nevertheless, this is an extre-
mely interesting and tractable system to study mechanisms
of drug resistance that are not simply caused by target loss
or pump upregulation.
12. Blocks in apoptosis or necroptosis
For a time, blocks in apoptosis were popular as an explanation
for drug pan-resistance. The concept is simple: drugs may kill
cancer cells by activating programmed cell death. Cells that
would inactivate that programme would obviously be more
resistant to killing and buy time for damage repair. There
was also appealing evidence to support the theory. Scott
Lowe and his collaborators [72] used a mouse lymphoma
model, driven by an activated Myc gene, that responded to
cytotoxic drugs with apoptosis. Inactivating the apoptotic pro-
gramme resulted in resistance. The versatile combination of in
vitro and in vivo experiments possible in this lymphoma system
resulted in a series of landmark papers that established that
blocks in apoptosis could reduce drug-induced cell kill, at
least in a lymphoma model highly susceptible to apoptotic
death. In this model, blocks in apoptosis also diminish suscep-
tibility to alkylating agents or X-rays. The resistance is
therefore a true pan-resistance.
It is in the generalization of this appealing concept to
tumours of epithelial origin in human patients that problems
arose. These problems have been discussed in detail [72,73]
and will not be reiterated here. The essence was summarized
by Brown & Attardi ([74], p. 236):
To become malignant, the cell must inactivate the apoptotic
pathway. As a consequence, the cell’s susceptibility to apoptosis
is severely compromised and other forms of death become
more important for cell killing and tumour response to
DNA-damaging agents.
This point has also been stressed by Blagosklonny [75].
Interestingly, even in the apoptosis-prone lymphoma
model of Lowe and co-workers [76], more recent experiments
have tended to de-emphasize blocks in apoptosis as a cause
of drug resistance. Resistance to doxorubicin was found to
be caused by downregulation of p53, Chk2 and Top2a
(encoding topoisomerase II, the target of doxorubicin); resist-
ance to camptothecin was caused by downregulation of Top1
(encoding topoisomerase 1, the target of camptothecin). No
evidence was found either for blocks in apoptosis as a
cause of resistance to a range of drugs in a conditional
breast cancer model in mice [77]. Attempts to improve
cancer chemotherapy in human cancer patients by inhibiting
apoptosis have not resulted in new standard treatments.
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6Since the early attempts to target apoptosis resistance in
cancer, a second programmed cell death pathway has been
characterized: necroptosis [78,79]. This involves leakage of
lysosomes and an explosive rupture of the dying cells.
Necroptosis is a key process in chronic inflammatory dis-
eases, but its role in cancer remains to be defined. Lethally
damaged cancer cells die by mitotic catastrophe or necrosis,
if not by apoptosis, but whether this necrosis is programmed
and involves the necroptosis pathway remains to be seen.
It is possible that cancer usually entails an effective inacti-
vation of all programmed death pathways and that this
inactivation is not complete in the exceptional tumours that
are cured by chemotherapy, such as leukaemias, lymphomas
or testicular cancer, as suggested by Blagosklonny [75]. Also,
tumours that are not cured often shrink under chemotherapy
and the cells appear to die by necrosis. It remains possible
that this process can be promoted by chemotherapy. Cell kill
by drugs or X-rays is often increased by inhibition of signal
transduction pathways [62], possibly interfering with the abil-
ity of pro-survival signalling to promote DNA repair [62]. The
possibility that tumour kill could be enhanced by reducing
blocks in programmed death pathways remains an interesting
one and retains ardent proponents [80].
13. Epithelial to mesenchymal transition
The EMTin carcinomas is invariablyassociatedwith the resist-
ancetoavarietyofanti-cancerdrugs.Notwithstandingamajor
worldwide effort to dissect mechanisms of drug resistance
associated with EMT, the picture is still foggy. The reason is
that EMT results in a massive reprogramming of gene
expression and it is difficult to sort out which alteration is
essential for each form of resistance [65]. Although it is easy
to demonstrate that EMT is associated with upregulation of
drug export pumps or of DNA repair mechanisms in cultured
cell lines [81], the relevance of these mechanisms for the high
degree of resistance of EMT tumours in vivo is not known.
EMT results in cells with properties resembling CSCs [65].
Hence, all drug resistance mechanisms invoked for stem cells
are also proposed for cancer cells that have undergone EMT
[82]. This is not very helpful, as it is not clear why CSCs are
drug-resistant or even whether this is always the case in real
tumours, as mentioned previously. There are new experimen-
tal tumour models resembling human tumours that
are accessible to detailed molecular studies. For instance,
Rottenberg & Jonkers (2012, personal communication) have
found that about half of the mammary carcinomas arising in
the p53, BRCA2-deficient mouse model [83] undergo EMT
and become unresponsive to chemotherapy. Although this is
a powerful system to study EMT-associated drug resistance,
these studies will not be plain sailing. Finding the alterations
responsible for resistance remains a search for needles in the
vast haystack of gene expression alterations.
14. Outlook
A vast amount of information is being published on drug
resistance mechanisms and on methods to restore sensitivity
to resistant cells using isolated cell lines. In the more ambi-
tious papers, attempts are made to couple this information
to the response of tumours in patient samples or in exper-
imental mouse tumours. Often, however, only cell lines are
studied. It is nearly always easier to kill tumour cells in a
test tube than in real tumours. Often there is doubt whether
results obtained in established cell lines can be extrapolated
to the behaviour of these cells when they were still in a
tumour [84]. This is why clever attempts to increase the effec-
tiveness of chemotherapy often fail clinically. From my
summary of the literature it should be clear that we still do
not know why. The most reasonable interpretation of the
cause of drug-resistant residual disease is the presence of
(semi)-quiescent cells; for pan-resistance there is not even a
generally accepted plausible hypothesis. I agree, however,
with Ira Mellman, vice-president for oncology research of
Genentech, that epigenetics is ‘the sleeping giant of drug
resistance’ (2012, personal communication). The field of
drug resistance has always been dominated by mutations in
analogy to bacterial resistance [85,86]. Mutations cause resist-
ance; selection of mutants results in the emergence of
resistance. The demonstration that cells can become pan-
resistant owing to widespread epigenetic alterations and
that such alterations can occur at a much higher frequency
than mutations is a major breakthrough, even though the
mechanism of resistance is still unclear.
Although studieson celllines remain essential foradding to
our knowledge of drug resistance mechanisms [87], it seems
obviousthat the ins and outs of residual disease and pan-resist-
ance can only be solved in tractable animal models, which
resemble human cancer sufficiently to allow extrapolation of
the results obtained to human disease. The mammalian
genomeisfiniteandthenumberofdrugresistancemechanisms
isfiniteaswell.GiventhepowerofDNAandRNAsequencing,
proteomics and bioinformatics, the job will get done.
Genetically modified mouse models should provide the
answers to even the most difficult questions [9,83,88–90].
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